Deterioration after corticosteroids in CIDP may be associated with pure focal demyelination pattern

BMC Neurology

Table 1 Clinical characteristics of patients with early deterioration

	Baseline			Time to endpoint (weeks)	Change at endpoint compared to baseline					Response to other treatments
	MRC	GS	INCAT-SS		ΔINCAT-DS	ΔRMI	ΔMRC	ΔGS	Δ INCAT-SS
1/D	48	51	np	5	1	-4	-2	-15	np^a	P
2/D	53	108	5	6	1	0	5	-52	-3	No
3/D	47	18	3	1	3	-7	-5	-5	1	IVIg
4/D	52	125	2	1	4	-10	-7	-25	0	IVIg
5/P	48	47	7	8	4	-7	-6	-27	-2	IVIg
6/P	50	9	11	2	3	-2	np	np	np	P
7/P	51	83	9	4	2	0	1	-47	5	No

Legend: Abbreviations: D dexamethasone, P prednisolone, np not performed, MRC Medical Research Council Sum Score (maximum of 60), MGS Mean Grip Strength (mean of both arms, Vigorimeter) INCAT-DS, Inflammatory Neuropathy Cause and Treatment Disability Scale (maximum score of 10, higher scores represent more disability), RMI Rivermead Mobility Index (maximum score of 15, higher scores represent less disability), INCAT-SS Inflammatory Neuropathy Cause and Treatment Sensory Sum Score (maximum score of 20, higher scores represent more sensory deficit). ^aINCAT-SS in this patient at time of deterioration was 10.

ISSN: 1471-2377